Ondansetron

also known as Zofran · Ondalenz · Ondansetron HCl · Ondansetron Hydrochloride · BEKINDA · Ondansetron (Zofran) · Zofran ODT · Zofran, Ondansetron hydrochloride · +31 more

Other / unclassified targets HTR3A via inhibition

Developed for: gastroenteritis · alcohol dependence · chemotherapy-induced toxicity · diarrheal disease · hypotensive disorder · irritable bowel syndrome · obsessive-compulsive disorder · schizophrenia
+44 more
· substance-related disorder · alcohol abuse · alcohol-related disorders · benign shuddering attacks · cancer · cholecystitis · cocaine dependence · drug dependence · hyperemesis gravidarum · intracranial hypotension · neuropathy, painful · poisoning · substance withdrawal syndrome · AChR+ myasthenia gravis · acute lung injury · acute respiratory distress syndrome · atrial fibrillation · childhood neoplasm · cholera · diabetes mellitus · dyspepsia · gastritis · gastroesophageal reflux disease · gastroparesis · headache disorder · juvenile idiopathic arthritis · methamphetamine dependence · neonatal abstinence syndrome · nicotine dependence · pain agnosia · radiation-induced disorder · thyroid cancer · traumatic brain injury · benign paroxysmal positional vertigo · bipolar disorder · cannabis dependence · cyclic vomiting syndrome · heart failure · infectious disease with sepsis · pancreas disorder · schizoaffective disorder · schizophreniform disorder · syncope, familial vasovagal · Tourette syndrome
Investigated by: National Institute on Alcohol Abuse and Alcoholism (NIAAA) · Tanta University · Merck Sharp & Dohme LLC · National Institute on Drug Abuse (NIDA) · University of Virginia · Algorithme Pharma Inc
+202 more
· Par Pharmaceutical, Inc. · Stanford University · Bankole Johnson · Forest Laboratories · GlaxoSmithKline · Mylan Pharmaceuticals Inc · National Cancer Institute (NCI) · Peking Union Medical College Hospital · The Hospital for Sick Children · Thrasher Research Fund · University of British Columbia · University of Colorado, Denver · Washington University School of Medicine · Aga Khan University · Ain Shams University · Assiut University · Bill and Melinda Gates Foundation · Dr. Stephen Freedman · Hamad Medical Corporation · Icahn School of Medicine at Mount Sinai · Institute of Neuroscience, Florence, Italy · Khon Kaen University · Mayo Clinic · Minia University · Mongi Slim Hospital · NHS Lothian · National Institute for Health Research, United Kingdom · RedHill Biopharma Limited · Sandoz · Sohag University · St. Justine's Hospital · Takeda · Teva Pharmaceuticals USA · University of Calgary · University of Manitoba · University of Maryland, Baltimore · University of Montreal · University of Nottingham · University of Texas · Yonsei University · Aarhus University Hospital · Acacia Pharma Ltd · Adial Pharmaceuticals · Adwia Pharma, Egypt · Agenzia Italiana del Farmaco · Air Liquide · Alberta Children's Hospital · Alberta Children's Hospital Research Institute · Alliance for Clinical Trials in Oncology · American Heart Association · Amgen · Ann & Robert H Lurie Children's Hospital of Chicago · Aquestive Therapeutics · Asan Medical Center · Assistance Publique - Hôpitaux de Paris · Australasian Leukaemia and Lymphoma Group · Barnsley Hospital NHS Foundation Trust · Barts & The London NHS Trust · Bispebjerg Hospital · Blood and Marrow Transplant Group of Georgia · Bnai Zion Medical Center · Bonsucesso Federal Hospital · Brest, Norman A., M.D. · Brown University · CHU de Quebec-Universite Laval · Canadian Institutes of Health Research (CIHR) · Catholic University of the Sacred Heart · Centre Hospitalier Universitaire Dijon · Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal · Chief Scientist Office of the Scottish Government · Children's Hospital Research Institute of Manitoba · Chinese Academy of Medical Sciences · Chongqing University Cancer Hospital · Chugai Pharma UK Limited · all 208 on the full record

Regulatory milestones approvals, filings & regulatory actions · 9 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansions (8)	US (FDA)	ZOFRAN	—	1993-02-02 – 2005-03-25	fda.gov ↗
Approved	US (FDA)	ZOFRAN	—	1991-01-04	fda.gov ↗

Trials 190 · started per year

today

US approved 1991

1990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 04 trials
Phase 0	NCT05819619	Jul 2023 → Apr 2024	—	Hackensack Meridian Health	Terminated	No outcome recorded Stop: Enrollment
Phase 0	NCT04891484	Apr 2021 → Apr 2022	nephrolithiasis	Mansoura University	Completed	No outcome recorded
Phase 0	NCT03125811	Jul 2017 → Mar 2023	—	Texas Tech University Health Sciences Center, El Paso	Completed	No outcome recorded
Phase 0	NCT01851993	Jun 2013 → Sep 2014	—	McGill University	Completed	No outcome recorded
Phase 128 trials · 2 met primary
Phase 1	NCT07310563	Dec 2024 → May 2025	obesity disorder	Amgen	Completed	No outcome recorded
Phase 1	NCT06297499	Aug 2024 → Aug 2025 overdue	—	Wayne State University	Recruiting	No outcome recorded
Phase 1	NCT05124067	Oct 2021 → Jan 2022	delirium	Tanta University	Completed	No outcome recorded
Phase 1	NCT03809234	May 2019 → Nov 2020	neuropathy, painful	Washington University School of Medicine	Terminated	No outcome recorded
Phase 1	NCT03583489	Jul → Aug 2018	—	Acacia Pharma Ltd	Completed	No outcome recorded
Phase 1	NCT02614586	Dec 2015 → Apr 2016	schizophrenia	Takeda	Terminated	No outcome recorded
Phase 1	NCT02460341	Aug 2015 → Feb 2017	—	Icahn School of Medicine at Mount Sinai	Completed	No outcome recorded
Phase 1	NCT02473887	Sep 2014 → Jan 2015	gastroenteritis	Hamad Medical Corporation	Completed	No outcome recorded
Phase 1	NCT01815125	Mar 2013 → Feb 2014	traumatic brain injury	St. Justine's Hospital	Completed	No outcome recorded
Phase 1	NCT01572012	Feb 2012 → Nov 2013	—	Halozyme Therapeutics	Completed	No outcome recorded
Phase 1	NCT01290276	Dec 2010 → Aug 2012	—	Tong Lee	Completed	No outcome recorded
Phase 1	NCT00981487	Feb → Mar 2009	—	Forest Laboratories	Completed	No outcome recorded
Phase 1	NCT01036854	Feb → Apr 2009	—	Forest Laboratories	Completed	No outcome recorded
Phase 1	NCT00905190	Feb → Mar 2009	—	Forest Laboratories	Completed	No outcome recorded
Phase 1	NCT01113164	Sep 2008 → Feb 2012	alcohol dependence	Brown University	Completed	Mixed
Phase 1	NCT01220167	Aug 2008	—	Aquestive Therapeutics	Completed	No outcome recorded
Phase 1	NCT00437229	Feb → May 2007	chemotherapy-induced toxicity	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT00649363	Jul 2005	—	Mylan Pharmaceuticals Inc	Completed	No outcome recorded
Phase 1	NCT00947128	Sep → Oct 2004	—	Sandoz	Completed	No outcome recorded
Phase 1	NCT00946387	Sep 2004	—	Sandoz	Completed	No outcome recorded
Phase 1	NCT00659685	Nov 2003 → ?	—	Par Pharmaceutical, Inc.	Completed	No outcome recorded
Phase 1	NCT00659074	Oct 2003 → Jan 2004	—	Par Pharmaceutical, Inc.	Completed	No outcome recorded
Phase 1	NCT00649532	Jul 2003	—	Mylan Pharmaceuticals Inc	Completed	No outcome recorded
Phase 1	NCT00648583	Jul 2003	—	Mylan Pharmaceuticals Inc	Completed	No outcome recorded
Phase 1	NCT00934921	Feb 2003	—	Teva Pharmaceuticals USA	Completed	Met primary
Phase 1	NCT00934180	Dec 2002	—	Teva Pharmaceuticals USA	Completed	Met primary
Phase 1	NCT00654277	Aug → Sep 2002	—	Par Pharmaceutical, Inc.	Completed	No outcome recorded
Phase 1	NCT00653458	Aug → Sep 2002	—	Par Pharmaceutical, Inc.	Completed	No outcome recorded

Phase 1/22 trials · 1 missed
Phase 1/2	NCT04603066	Jan 2021 → Oct 2023	neuropathy, painful	Washington University School of Medicine	Completed	Missed primary
Phase 1/2	NCT01217190	Sep 2008	chemotherapy-induced toxicity	MonoSol Rx	Completed	No outcome recorded
Phase 234 trials · 1 met primary · 3 missed
Phase 2	NCT07795060	Mar → Dec 2027 expected	cholera	Public Interest Science Center	Not yet recruiting	No outcome recorded
Phase 2	NCT07381634	Mar → Dec 2026 expected	hepatocellular carcinoma	First Affiliated Hospital of Wenzhou Medical University	Not yet recruiting	No outcome recorded
Phase 2	NCT04226170	Nov 2023 → Apr 2025	AChR+ myasthenia gravis	DAS-MG, Inc	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT05378113	May → Aug 2023	—	Emory University	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT05342818	Apr → Jul 2022	gastroparesis	Tanta University	Completed	No outcome recorded
Phase 2	NCT05202574	Sep 2021 → Feb 2022	intracranial hypotension	Minia University	Unknown	No outcome recorded
Phase 2	NCT04557189	Oct 2020 → Mar 2022	—	Takeda	Completed	Met primary
Phase 2	NCT06289335	Aug 2020 → Sep 2021	—	Hospital Central "Dr. Ignacio Morones Prieto"	Completed	No outcome recorded
Phase 2	NCT04468685	Jul → Dec 2020	cholecystitis	National Hepatology & Tropical Medicine Research Institute	Completed	No outcome recorded
Phase 2	NCT03865290	Apr 2019 → Mar 2028 expected	diabetes mellitus, dyspepsia	Mayo Clinic	Recruiting	No outcome recorded
Phase 2	NCT03785691	Mar 2019 → Jul 2022	hyperemesis gravidarum	Nordsjaellands Hospital	Terminated	Mixed Stop: Enrollment
Phase 2	NCT04362449	Jan 2019 → Feb 2023	gallbladder cancer	Imperial College Healthcare NHS Trust	Unknown	No outcome recorded
Phase 2	NCT03572829	Mar 2018 → Jan 2020	chemotherapy-induced toxicity, head and neck squamous cell carcinoma	Chinese Academy of Medical Sciences	Completed	No outcome recorded
Phase 2	NCT02757105	May 2016 → Jun 2017	irritable bowel syndrome	RedHill Biopharma Limited	Completed	No outcome recorded
Phase 2	NCT00890149	Sep 2015 → Sep 2016	alcohol abuse, alcohol dependence	University of Maryland, Baltimore	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT02354703	Aug 2015 → Mar 2020	alcohol-related disorders	University of Maryland, Baltimore	Completed	Missed primary
Phase 2	NCT01965704	Sep 2014 → Sep 2020	drug dependence, neonatal abstinence syndrome	Stanford University	Completed	Missed primary
Phase 2	NCT02006056	Nov 2013 → Jun 2014	—	Sunnybrook Health Sciences Centre	Completed	No outcome recorded
Phase 2	NCT01841606	Mar → Dec 2013	—	University of British Columbia	Completed	No outcome recorded
Phase 2	NCT01370408	Feb 2012 → Mar 2016	chemotherapy-induced toxicity	Northside Hospital, Inc.	Completed	No outcome recorded
Phase 2	NCT01275248	Jan 2011 → Sep 2015	obsessive-compulsive disorder	Transcept Pharmaceuticals	Terminated	No outcome recorded
Phase 2	NCT01254877	Dec 2010 → Jan 2017	alcohol abuse, alcohol dependence	Johns Hopkins University	Completed	No outcome recorded
Phase 2	NCT00795769	Aug 2008 → Jun 2009	Burkitt lymphoma, Hodgkins lymphoma, MALT lymphoma, acute myeloid leukemia with 11q23 abnormalities +29	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 2	NCT00689572	Jul 2008 → Dec 2013	cocaine dependence	University of Virginia	Completed	Missed primary
Phase 2	NCT01543945	Mar 2008 → Dec 2011	—	Prince of Songkla University	Completed	No outcome recorded
Phase 2	NCT00678457	Jan 2007 → May 2008	alcohol dependence	University of Virginia	Completed	No outcome recorded
Phase 2	NCT00285051	Nov 2005 → Feb 2009	cancer	Rafa Laboratories	Terminated	No outcome recorded
Phase 2	NCT00183222	May → Dec 2005	alcohol dependence	Medical University of South Carolina	Completed	No outcome recorded
Phase 2	NCT00006205	Mar 2005 → Jun 2013	alcohol dependence	Bankole Johnson	Unknown	No outcome recorded
Phase 2	NCT00040053	Jun 2002 → Feb 2004	methamphetamine dependence	National Institute on Drug Abuse (NIDA)	Completed	No outcome recorded
Phase 2	NCT00027079	Sep 2001 → Aug 2004	alcohol dependence	National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Completed	No outcome recorded
Phase 2	NCT00033085	May 2001 → Dec 2002	substance-related disorder	National Institute on Drug Abuse (NIDA)	Completed	No outcome recorded
Phase 2	NCT00000289	May 1998 → Dec 2001	nicotine dependence	National Institute on Drug Abuse (NIDA)	Completed	No outcome recorded
Phase 2	NCT00000443	? → Apr 2000	alcohol dependence	National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Completed	No outcome recorded

Phase 2/34 trials · 1 missed
Phase 2/3	NCT07588217	Oct 2026 → Oct 2028 expected	acute lung injury, acute respiratory distress syndrome	Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal	Not yet recruiting	No outcome recorded
Phase 2/3	NCT03052361	Jul 2017 → Sep 2020	gastroenteritis	St. Justine's Hospital	Terminated	No outcome recorded Stop: Enrollment
Phase 2/3	NCT01591291	Jun 2012 → Dec 2017	alcohol dependence	University of Virginia	Withdrawn	No outcome recorded
Phase 2/3	NCT01414777	Nov 2009 → Jun 2011	hypotensive disorder, pregnancy disorder	University of Virginia	Completed	Missed primary
Phase 327 trials · 2 met primary · 3 missed
Phase 3	NCT05876585	Jun 2025 overdue	gastroenteritis	Genuine Research Center, Egypt	Not yet recruiting	No outcome recorded
Phase 3	NCT06282211	Feb → Mar 2024	—	The First Affiliated Hospital of Xinxiang Medical College	Unknown	No outcome recorded
Phase 3	NCT06208917	Jul 2023 → Jul 2026 overdue	childhood neoplasm	Yizhuo Zhang	Recruiting	No outcome recorded
Phase 3	NCT05872893	Jun 2023 → Jan 2025	childhood malignant neoplasm	Immune Oncology Research Institute	Completed	No outcome recorded
Phase 3	NCT05620641	Oct 2022 → Feb 2025	morbid obesity	Tanta University	Completed	No outcome recorded
Phase 3	NCT04703088	Jun → Aug 2021	hypotensive disorder	Laval University	Unknown	No outcome recorded
Phase 3	NCT05087615	Mar → Aug 2021	—	Shahid Beheshti University of Medical Sciences	Completed	No outcome recorded
Phase 3	NCT04101227	Feb 2020 → Feb 2022	alcohol-related disorders	Adial Pharmaceuticals	Completed	Missed primary
Phase 3	NCT03817970	Nov 2019 → Sep 2027 expected	cisplatin toxicity	University of Colorado, Denver	Active not recruiting	No outcome recorded
Phase 3	NCT03851835	Sep 2019 → Jun 2024	diarrheal disease, gastroenteritis, viral infectious disease	University of Calgary	Completed	Met primary
Phase 3	NCT03555188	Mar 2018 → Aug 2020	irritable bowel syndrome	University of Leeds	Completed	Missed primary
Phase 3	NCT03330119	Oct 2017 → Jun 2018	pregnancy disorder, substance-related disorder	Brest, Norman A., M.D.	Terminated	No outcome recorded Stop: Business
Phase 3	NCT02619201	Nov 2015 → May 2016	gastroenteritis	Hospital General Naval de Alta Especialidad - Escuela Medico Naval	Unknown	No outcome recorded
Phase 3	NCT02246439	Dec 2014 → Feb 2017	gastritis, gastroenteritis	RedHill Biopharma Limited	Completed	Met primary
Phase 3	NCT02028910	Jan → Oct 2014	gastroenteritis	Assistance Publique - Hôpitaux de Paris	Terminated	No outcome recorded
Phase 3	NCT01536392	Mar 2012 → Oct 2019	cervical cancer	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 3	NCT01432977	Sep 2011 → Jun 2012	pain agnosia	University Hospital, Limoges	Completed	No outcome recorded
Phase 3	NCT01257672	Jul 2011 → Nov 2013	gastroenteritis	IRCCS Burlo Garofolo	Completed	No outcome recorded
Phase 3	NCT00768508	Sep 2008 → Dec 2012	alcohol dependence	Bankole Johnson	Completed	No outcome recorded
Phase 3	NCT00382642	Jun 2006 → Mar 2009	alcohol dependence	Bankole Johnson	Completed	No outcome recorded
Phase 3	NCT00147355	Nov 2005 → Nov 2008	HIV infectious disease	Kirby Institute	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT00149734	Jan 2005 → May 2010	schizophrenia	University of Colorado, Denver	Completed	No outcome recorded
Phase 3	NCT00090246	May 2004 → Apr 2005	—	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT00090155	Sep 2003 → Nov 2004	—	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT00642512	Jul 2003 → Jul 2004	chemotherapy-induced toxicity	Solvay Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00020657	Jul 2001 → Oct 2004	cancer of unknown primary site	Gary Morrow	Completed	Missed primary
Phase 3	NCT00006348	Oct 2000 → Sep 2001	childhood malignant neoplasm, leukemia, myelodysplastic syndrome, myeloproliferative neoplasm +3	Alliance for Clinical Trials in Oncology	Completed	No outcome recorded

Phase 445 trials · 4 met primary · 6 missed
Phase 4	NCT07858149	Sep 2026 → Jan 2027 expected	—	Istanbul University	Not yet recruiting	No outcome recorded
Phase 4	NCT07681076	Sep → Nov 2026 expected	—	Karuna Therapeutics, Inc.	Recruiting	No outcome recorded
Phase 4	NCT07638527	Sep 2026 → Mar 2027 expected	—	Faisalabad Medical University	Recruiting	No outcome recorded
Phase 4	NCT07740577	Jul 2026 → Jan 2027 expected	—	Sanliurfa Education and Research Hospital	Recruiting	No outcome recorded
Phase 4	NCT07336680	Feb → Jul 2026	—	Peking Union Medical College Hospital	Completed	No outcome recorded
Phase 4	NCT06632184	Dec 2025 → Mar 2026 overdue	—	Mexican Social Security Institute	Active not recruiting	Met primary
Phase 4	NCT07264738	Jul → Sep 2025 overdue	—	Peking Union Medical College Hospital	Active not recruiting	No outcome recorded
Phase 4	NCT05844501	Apr 2025 → Dec 2027 expected	atrial fibrillation	Indiana University	Recruiting	No outcome recorded
Phase 4	NCT07217600	Mar 2025 → Mar 2026 overdue	childhood malignant neoplasm, radiation-induced disorder	Chongqing University Cancer Hospital	Recruiting	No outcome recorded
Phase 4	NCT06747975	Jan 2025 → Jan 2026 overdue	—	Assiut University	Not yet recruiting	No outcome recorded
Phase 4	NCT06729307	Jan 2025 → Jan 2026 overdue	—	Peking Union Medical College Hospital	Not yet recruiting	No outcome recorded
Phase 4	NCT06704139	Dec 2024 → Dec 2026 expected	—	Assiut University	Not yet recruiting	No outcome recorded
Phase 4	NCT06697782	Jul → Dec 2024	thyroid cancer	The First Affiliated Hospital of Zhengzhou University	Completed	No outcome recorded
Phase 4	NCT05583214	Oct → Dec 2022	—	Muhammad Mubariz	Unknown	No outcome recorded
Phase 4	NCT05127876	Jan → Mar 2022	—	Ain Shams University	Completed	No outcome recorded
Phase 4	NCT04318847	Oct 2021 → Apr 2023	—	Lizar Aguirre Pascasio	Unknown	No outcome recorded
Phase 4	NCT05439772	Jan 2021 → Jul 2023	diarrheal disease, eosinophilic gastroenteritis, inflammatory bowel disease	State University of New York - Downstate Medical Center	Completed	Missed primary
Phase 4	NCT06927817	Nov 2020 → Nov 2021	cholecystitis	University of Health Sciences	Completed	No outcome recorded
Phase 4	NCT03833999	Oct 2018 → Jun 2019	intestinal motility disease	University of Nottingham	Completed	No outcome recorded
Phase 4	NCT07068230	Oct 2018 → Sep 2019	headache disorder	Minia University	Completed	No outcome recorded
Phase 4	NCT03503292	May 2018 → Dec 2019	—	Mayo Clinic	Completed	No outcome recorded
Phase 4	NCT03262038	Dec 2017 → Aug 2019	—	University of Michigan	Terminated	Missed primary
Phase 4	NCT03297021	Oct 2017 → Apr 2019	—	Icahn School of Medicine at Mount Sinai	Completed	No outcome recorded
Phase 4	NCT03035942	Jan 2017 → Oct 2018	disease of bone structure, poisoning	Pontifical Catholic University of São Paulo	Completed	No outcome recorded
Phase 4	NCT02928601	Nov 2016 → Aug 2017	—	Cukurova University	Completed	No outcome recorded
Phase 4	NCT02468323	Oct 2015 → Feb 2017	—	Hospital de Base	Completed	No outcome recorded
Phase 4	NCT02541019	Oct 2015 → Jan 2017	—	Bonsucesso Federal Hospital	Completed	No outcome recorded
Phase 4	NCT02803788	Jul 2015 → Jul 2016	—	Government Medical College, Haldwani	Unknown	No outcome recorded
Phase 4	NCT01870635	May 2014 → Jan 2017	diarrheal disease, gastroenteritis	Dr. Stephen Freedman	Completed	Missed primary
Phase 4	NCT01870648	May 2014 → Dec 2017	diarrheal disease, gastroenteritis	Dr. Stephen Freedman	Completed	Missed primary
Phase 4	NCT02985840	Jan 2014 → Nov 2016	—	OhioHealth	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT01876290	May 2013 → Jan 2014	—	Hopital Foch	Completed	Missed primary
Phase 4	NCT02382146	Apr 2012 → Dec 2014	—	Yeditepe University Hospital	Completed	No outcome recorded
Phase 4	NCT01913990	Sep 2011 → Aug 2017	—	Ottawa Hospital Research Institute	Unknown	Met primary
Phase 4	NCT01050270	Sep 2010 → Dec 2012	poisoning	University of Edinburgh	Completed	Met primary
Phase 4	NCT01303536	Dec 2009 → Mar 2010	obsessive-compulsive disorder	Institute of Neuroscience, Florence, Italy	Completed	No outcome recorded
Phase 4	NCT00878228	Apr 2009 → Jan 2010	—	Hospital for Special Surgery, New York	Completed	No outcome recorded
Phase 4	NCT00745004	Jan 2009 → Jul 2011	irritable bowel syndrome	University of Nottingham	Completed	No outcome recorded
Phase 4	NCT00793663	Nov 2008 → Apr 2011	—	RWTH Aachen University	Completed	No outcome recorded
Phase 4	NCT01165866	Jun → Dec 2008	gastroenteritis	Hamad Medical Corporation	Completed	Missed primary
Phase 4	NCT00796497	Mar → Nov 2008	obsessive-compulsive disorder	Institute of Neuroscience, Florence, Italy	Completed	No outcome recorded
Phase 4	NCT00674713	Jan 2006 → Sep 2007	cholelithiasis	Catholic University of the Sacred Heart	Completed	No outcome recorded
Phase 4	NCT00090207	Jan → Sep 2004	—	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 4	NCT00429832	Oct 2003 → Nov 2005	—	University of New Mexico	Completed	Met primary
Phase 4	NCT00092183	Oct 2002 → Dec 2003	breast cancer	Merck Sharp & Dohme LLC	Completed	No outcome recorded

Phase not applicable46 trials · 4 met primary · 1 missed
—	NCT07632144	Jun → Jul 2026 overdue	—	Mongi Slim Hospital	Not yet recruiting	No outcome recorded
—	NCT07511491	Apr → Aug 2026 overdue	—	Tanta University	Recruiting	No outcome recorded
—	NCT07489742	Mar → Sep 2026 overdue	—	Tanta University	Recruiting	No outcome recorded
—	NCT07377903	Feb → Jul 2026 overdue	—	Sohag University	Not yet recruiting	No outcome recorded
—	NCT06898268	Jul → Dec 2024	gastroesophageal reflux disease	Muhammad Aamir Latif	Completed	No outcome recorded
—	NCT06423820	May 2024 → Jan 2025	strabismus	Tanta University	Completed	No outcome recorded
—	NCT06423807	May → Sep 2024	benign shuddering attacks	Tanta University	Completed	No outcome recorded
—	NCT06371014	May → Dec 2024	—	Shanghai Children's Medical Center	Unknown	No outcome recorded
—	NCT06300346	Mar → Aug 2024	—	Sohag University	Unknown	No outcome recorded
—	NCT06254131	Feb → Oct 2024	—	Tanta University	Completed	No outcome recorded
—	NCT06080880	Dec 2023 → Nov 2025 overdue	chemotherapy-induced toxicity	Hubei Cancer Hospital	Recruiting	No outcome recorded
—	NCT06444737	Nov 2023 → Jun 2024	intracranial hypotension	Mongi Slim Hospital	Unknown	No outcome recorded
—	NCT06175806	Sep → Nov 2023	—	Ain Shams University	Completed	No outcome recorded
—	NCT05475873	Jun → Oct 2023	—	General Hospital of Ningxia Medical University	Completed	Met primary
—	NCT04499274	Sep 2020 → Nov 2023	blood coagulation disease	Seoul National University Bundang Hospital	Unknown	No outcome recorded
—	NCT07334223	Jul 2020 → Jan 2021	benign shuddering attacks	Mayo Hospital Lahore	Completed	No outcome recorded
—	NCT05076461	Jul 2020 → Jun 2021	gastroenteritis	Tehsil Headquarter Hospital	Completed	No outcome recorded
—	NCT04294992	Apr → Sep 2020	—	Kasr El Aini Hospital	Unknown	No outcome recorded
—	NCT04169828	Aug 2019 → Jan 2025	juvenile idiopathic arthritis	University of British Columbia	Completed	No outcome recorded
—	NCT03859102	Dec 2018 → Oct 2019	aneurysm or dilatation of ascending aorta, aortic valve disorder, cardiac valvular defect, coronary artery disorder +2	James Cook University Hospital	Unknown	No outcome recorded
—	NCT02966041	Mar → Jul 2018	—	University of British Columbia	Completed	Met primary
—	NCT05590936	Jan 2018 → Dec 2022	—	University of Thessaly	Completed	No outcome recorded
—	NCT03182179	Nov 2016 → Nov 2021	rectal cancer	Ente Ospedaliero Cantonale, Bellinzona	Completed	No outcome recorded
—	NCT02901054	Aug → Nov 2016	—	Washington University School of Medicine	Completed	No outcome recorded
—	NCT02793843	Jun 2016 → Jun 2017	—	Makassed General Hospital	Completed	No outcome recorded
—	NCT02883192	Feb → Oct 2016	—	Bnai Zion Medical Center	Unknown	No outcome recorded
—	NCT02862873	Mar → May 2015	hypotensive disorder	Centre Hospitalier Universitaire Dijon	Terminated	No outcome recorded
—	NCT03685032	Aug 2014 → Feb 2016	—	Khon Kaen University	Completed	No outcome recorded
—	NCT02026778	Dec 2013 → Nov 2014	—	Yonsei University	Completed	No outcome recorded
—	NCT01668069	Oct 2012	hyperemesis gravidarum	United States Naval Medical Center, San Diego	Completed	Met primary
—	NCT01843868	Jan 2012 → Jun 2015	non-Hodgkin lymphoma	Australasian Leukaemia and Lymphoma Group	Withdrawn	No outcome recorded Stop: Enrollment
—	NCT01477242	Nov 2011 → May 2012	—	Seoul National University Hospital	Unknown	No outcome recorded
—	NCT01549652	Apr 2011 → Apr 2015	drug dependence, substance withdrawal syndrome	Stanford University	Completed	Missed primary
—	NCT01640340	Jan → Aug 2011	cancer	Ohio State University Comprehensive Cancer Center	Completed	No outcome recorded
—	NCT01006707	Nov 2010 → Jul 2013	substance-related disorder	Stanford University	Completed	No outcome recorded
—	NCT01759706	Oct 2010 → Dec 2012	pancreatic neoplasm	Vita-Salute San Raffaele University	Completed	No outcome recorded
—	NCT01169805	Aug 2010 → Jun 2011	non-congenital cyst of kidney	Yonsei University	Completed	No outcome recorded
—	NCT01067677	Feb 2010 → Feb 2012	—	Franklyn Cladis	Withdrawn	No outcome recorded Stop: Business
—	NCT01216410	Dec 2008 → Apr 2011	—	Duke University	Completed	Met primary
—	NCT00695864	May 2008 → Jul 2009	substance withdrawal syndrome	Stanford University	Completed	No outcome recorded
—	NCT00599573	Oct 2007 → Jul 2010	HIV infectious disease, cocaine dependence	University of Virginia	Unknown	No outcome recorded
—	NCT00499668	Aug 2007 → Jan 2008	leukemia, lymphoproliferative syndrome, myelodysplastic syndrome, myeloproliferative neoplasm +1	Vanderbilt-Ingram Cancer Center	Withdrawn	No outcome recorded Stop: Enrollment
—	NCT00199329	Jan 2005 → ?	—	Khon Kaen University	Completed	No outcome recorded
—	NCT00120744	Jan 2004 → Apr 2005	diarrheal disease, gastroenteritis	The Hospital for Sick Children	Completed	No outcome recorded
—	NCT00387556	Dec 2002 → Dec 2006	—	University of Colorado, Denver	Completed	No outcome recorded
—	NCT00018850	Jun 1998 → Jun 2003	schizophrenia	US Department of Veterans Affairs	Completed	No outcome recorded

Comparator or background therapy271 trials
Phase 0	NCT07662200 Comparator	Aug 2026 → Aug 2027 expected	malignant germ cell tumor	Ottawa Hospital Research Institute	Not yet recruiting	No outcome recorded
Phase 0	NCT04682743 Comparator	Jan 2021 → Jan 2022	—	Cairo University	Completed	No outcome recorded
Phase 0	NCT03593811 Comparator	Aug 2018 → Apr 2021	—	Vanderbilt University Medical Center	Completed	No outcome recorded
Phase 0	NCT03475693 Background	Sep 2017 → Nov 2019	traumatic encephalopathy	Corewell Health South	Completed	No outcome recorded
Phase 0	NCT00314743 Background	Oct 2005 → Dec 2008	—	Washington University School of Medicine	Completed	No outcome recorded
Show all 271 trials opens the full record — a long page

News releases announcing trial results or a regulatory action · 35

Date	Issuer	Release
2026-06-09	Nasus Pharma	Results Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003) nasuspharma.com ↗ Data showed that NS003 had a PK profile comparable to IV, with similar time to maximum concentration (Tmax) and area under the curve (AUC) results.
2026-04-27	Adial Pharmaceuticals	Regulatory Adial Pharmaceuticals Submits Application to FDA Commissioner's National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program adial.com ↗
2025-05-08	Adial Pharmaceuticals	Regulatory Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration adial.com ↗ Adial Pharmaceuticals, Inc. ( NASDAQ: ADIL ) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that the FDA has granted Adial’s request for an End of Phase 2 meeting to discuss Adial’s proposed clinical development plan and seek FDA guidance on the Phase 3 adaptive with enrichment design of the upcoming clinical trial for AD04.
2025-02-25	Adial Pharmaceuticals	Regulatory Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04 adial.com ↗ Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced a positive response from the U.S. Food and Drug Administration (FDA) regarding its proposed in vitro bridging strategy for AD04.
2025-01-29	Adial Pharmaceuticals	Results Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder adial.com ↗ These study results support the near micro-dosing regimen planned for use in the upcoming registration trials for AD04 and conform with the FDA’s bridging requirements for a 505(b)(2) registration pathway.
2024-11-14	Adial Pharmaceuticals	Results Adial Pharmaceuticals Announces Positive Topline Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder adial.com ↗ Completion of this study also satisfied an FDA requirement for the upcoming Phase 3 clinical trials of AD04.
2024-06-20	Adial Pharmaceuticals	Results Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder adial.com ↗ The publication findings showed a significant difference in the monthly percentage of heavy drinking days between the Company’s lead asset, AD04 (low-dose ondansetron), and the placebo group among heavy drinking patients with Alcohol Use Disorder (AUD) and specific genotypic variants.
2024-04-10	Adial Pharmaceuticals	Results Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder adial.com ↗ According to the publication, low-dose AD04 did not significantly change biochemical markers of liver injury, such as ALT, AST, and Serum Bilirubin.
2022-07-20	Adial Pharmaceuticals	Results Adial Pharmaceuticals Announces Topline Results For Onward™ Phase 3 Trial for AD04 in Patients with Alcohol Use Disorder adial.com ↗ AD04 achieved statistically significant mean reduction in heavy drinking days among the pre-specified group of “heavy drinkers” (defined below).
2021-06-24	Adial Pharmaceuticals	Regulatory Adial Pharmaceuticals Provides Regulatory and Development Update adial.com ↗ The Company is reporting that on June 23, 2021, it received notice from the FDA that its request for Fast Track Designation has been denied at this time.
2020-10-21	Adial Pharmaceuticals	Regulatory Adial Pharmaceuticals Announces FDA Reactivation of its Investigational New Drug Application for AD04 in Alcohol Use Disorder adial.com ↗ today announced that the U.S. Food and Drug Administration (FDA) has reactivated Adial’s U.S. Investigational New Drug (IND) application and lifted the clinical hold from AD04, a genetically-targeted therapeutic agent for the treatment of Alcohol Use Disorder (AUD).
2020-07-28	RedHill Biopharma Limited	Results RedHill Biopharma Publishes Positive IBS-D Phase 2 Study Data in The American Journal of Gastroenterology redhillbio.com ↗ The newly published positive data in patients who received RHB-102 for IBS-D, are a demonstration of RedHill’s ongoing ability to successfully execute its R&D programs to meet specified endpoints.
2020-07-22	Adial Pharmaceuticals	Regulatory Adial Pharmaceuticals Receives European Medicines Agency (EMA) Agreement on the Pediatric Investigation Plan (PIP) for AD04 in Alcohol Use Disorder adial.com ↗
2020-06-11	Adial Pharmaceuticals	Regulatory Adial Pharmaceuticals Announces Approval to Commence Landmark ONWARD(TM) Pivotal Phase 3 Trial in Poland adial.com ↗
2020-01-09	Adial Pharmaceuticals	Regulatory Adial Pharmaceuticals Receives Approval to Commence Phase 3 Trial in Finland adial.com ↗ today announced that it has received favorable opinions from the Finnish Medicines Agency (FIMEA) and National Committee on Medical Research Ethics (TUKIJA) to commence its Phase 3 study
2019-12-19	Adial Pharmaceuticals	Regulatory Adial Pharmaceuticals Submits Clinical Trial Applications in Six Additional European Countries adial.com ↗ today announced that it has submitted Clinical Trial Applications (CTAs) to commence its first Phase 3 trial in Finland, Estonia, Latvia, Poland, Bulgaria, and Croatia.
2019-11-12	RedHill Biopharma Limited	Results RedHill Biopharma Announces Publication of RHB-102 Gastroenteritis Phase 3 Study Results in JAMA redhillbio.com ↗ The GUARD study met its primary endpoint, prevention of further vomiting for at least 24 hours among adolescents and adults with gastroenteritis-related emesis without the usage of intravenous hydration or rescue medication.
2019-10-01	Adial Pharmaceuticals	Regulatory Adial Files Clinical Trial Application to Commence Phase 3 Trial adial.com ↗ today announced that it has submitted its Clinical Trial Application (CTA) to commence the Phase 3 clinical trial
2019-09-05	Adial Pharmaceuticals	Regulatory Adial Pharmaceuticals Completes Key Regulatory Milestone Prior to Commencing European Phase 3 Clinical Trial of AD04 for the Treatment of Alcohol Use Disorder adial.com ↗ today announced that the European Medicines Agency (EMA) has validated the Pediatric Investigation Plan (PIP) waiver application for AD04, the Company’s lead investigational new drug product for the treatment of Alcohol Use Disorder (AUD).
2018-05-30	RedHill Biopharma Limited	Results RedHill Biopharma to Present Positive Phase II Results of BEKINDA® for IBS-D at Digestive Disease Week 2018 redhillbio.com ↗ The Phase II study with BEKINDA® 12 mg successfully met its primary endpoint, improving the primary efficacy outcome of stool consistency (per FDA guidance definition) by an absolute difference of 20.7% vs. placebo (p-value=0.036).
2018-03-26	RedHill Biopharma Limited	Results RedHill Biopharma Announces DDW 2018 Poster of Distinction on Positive Phase II Results with BEKINDA® for IBS-D redhillbio.com ↗ The Phase II study with BEKINDA® 12 mg successfully met its primary endpoint, improving the primary efficacy outcome of stool consistency (per FDA guidance definition) by an absolute difference of 20.7% vs. placebo (p-value=0.036).
2018-01-16	RedHill Biopharma Limited	Results RedHill Biopharma Announces Final Results from Phase II Study with BEKINDA® for IBS-D redhillbio.com ↗ RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal diseases and cancer, today announced top-line final results1 from the Phase II clinical study with BEKINDA® 12 mg (RHB-102)2 for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D).
2017-10-03	RedHill Biopharma Limited	Results RedHill Biopharma Announces Positive Top-Line Results from Phase II Study of BEKINDA in Patients with IBS-D redhillbio.com ↗ BEKINDA®i 12 mg Phase II study successfully met its primary endpoint, improving primary efficacy outcome of stool consistency by an absolute difference of 19.4% vs. placebo
2017-10-03	RedHill Biopharma Limited	Results RedHill Biopharma Announces Positive Top-Line Results from Phase II Study of BEKINDA® in Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) redhillbio.com ↗ BEKINDA®i 12 mg Phase II study successfully met its primary endpoint, improving primary efficacy outcome of stool consistency by an absolute difference of 19.4% vs. placebo and comparing favorably with previously reported outcomes from studies of Xifaxan® (rifaximin) and Viberzi® (eluxadoline)ii
2017-06-14	RedHill Biopharma Limited	Results RedHill Biopharma Announces Successful Phase III Top-Line Results with BEKINDA® for Acute Gastroenteritis redhillbio.com ↗ RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced positive top-line results from the Phase III GUARD study with BEKINDA® (RHB-102)1 24 mg for acute gastroenteritis and gastritis.
2016-02-11	RedHill Biopharma Limited	Results RedHill Biopharma Announces Successful PK Study With BEKINDA™ 12 mg and Submission to FDA of IBS-D Phase II Study Protocol redhillbio.com ↗
2015-09-28	Heron Therapeutics	Results Heron Therapeutics Announces Oral Presentation of Data from Completed Phase 3 MAGIC Study for SUSTOL® at the ASCO Breast Cancer Symposium herontx.com ↗ These data were presented in an oral presentation and poster titled “Phase III Study of APF530 versus Ondansetron with a Neurokinin 1 Antagonist + Corticosteroid in Preventing Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: MAGIC Trial.”
2014-12-31	RedHill Biopharma Limited	Regulatory RedHill Biopharma Announces Acceptance for Review of BEKINDA(TM) European Marketing Application for Oncology Support redhillbio.com ↗ The UK MHRA has validated the European marketing application for the indications of chemotherapy and radiotherapy-induced nausea and vomiting; MHRA's feedback is expected during H2/2015
2014-12-09	RedHill Biopharma Limited	Regulatory RedHill Biopharma Submits BEKINDA™ (RHB-102) European Marketing Authorization Application for Oncology Support redhillbio.com ↗ The European marketing authorization application (MAA) seeks approval of BEKINDA™ for cancer patients suffering from chemotherapy and radiotherapy-induced nausea and vomiting
2014-05-22	RedHill Biopharma Limited	Regulatory RedHill Biopharma Announces FDA Clearance for Phase III Study with RHB-102 Planned to Commence in Q3 2014 redhillbio.com ↗ FDA’s clearance of RedHill’s Investigational New Drug (“IND”) amendment allows the initiation of a Phase III clinical study for a new undisclosed indication with RHB-102[1], a proprietary, once-daily, extended release oral pill formulation of the antiemetic drug ondansetron
2014-04-30	RedHill Biopharma Limited	Results RedHill Biopharma Reports Successful RHB-102 Bioavailability Clinical Trial and Planned Submission of European Marketing Application in Q3/2014 redhillbio.com ↗ RedHill received positive results from a comparative bioavailability clinical trial which included 20 healthy volunteers
2013-10-08	RedHill Biopharma Limited	Results RedHill Biopharma Reports Positive PK Clinical Studies Towards Planned NDA with RHB-102 (Anti-Emetic) redhillbio.com ↗ today reported positive results from two supplementary pharmacokinetic (PK) studies with RHB-102, an anti-emetic oncology-support drug.
2010-08-06	Lannett Company, Inc.	Regulatory LANNETT RECEIVES FDA APPROVAL FOR ONDANSETRON INJECTION, USP 2 MG/ML SINGLE-DOSE VIALS PDF Version investorroom.com ↗ Philadelphia, PA – August 6, 2010 – Lannett Company, Inc. (AMEX: LCI), a manufacturer of generic pharmaceuticals, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Ondansetron Injection USP, 2 mg/mL, Single-Dose Vials.
2007-06-26	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory Teva Announces Approval Of Ondansetron Hcl Tablets And Ondansetron Orally Disintegrating Tablets USP tevapharm.com ↗ Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted approval for the Company's Abbreviated New Drug Applications (ANDA) to market Ondansetron Hydrochloride Tablets, 4 mg, 8 mg and 24 mg and Ondansetron Orally Disintegrating Tablets USP, 4 mg and 8 mg.
2006-02-26	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory Teva Announces Tentative Approval of Ondansetron Injection USP tevapharm.com ↗ Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted tentative approval for the Company's ANDAs for Ondansetron Injection USP

All press releases naming this drug 118 releases

Date	Issuer	Release
Show all 118 releases opens the full record — a long page

Evidence & citations 44 cited values

Every value below carries the sentence it was read from. 463 sources stand behind the page.

Field	Value	Cited text
Known as	Ondansetron	“METHODS: Women scheduled for elective cesarean delivery were randomized to one of three groups: placebo (placebo plus placebo); metoclopramide (metoclopramide 10 mg plus...” PMID 23635626 ↗ Mar 2013 444 “5HT3 (5-Hydroxytryptamine 3) antagonists (ondansetron, granisetron or tropisetron) used as the local institutional standard of care will be permitted, although the preferential...” NCT01843868 ↗ “Comparing the Effects of Ondansetron Versus Dexamethasone on the Incidence of Post-dural Puncture Headache (PDPH) , Nausea and Vomiting After Spinal Anaesthesia of Parturients...” NCT05202574 ↗ “30 minutes prior to emergence 0.2 μg/kg total body weight Sufentanil IV and 1 gram of paracetamol IV (if 6hrs since preoperative medicine) and 4 mg ondansetron IV (PONV...” NCT04248179 ↗ “Placebo, given orally Ranitide 50 mg, IV, before chemotherapy (D1) Ondansetron 8 mg, IV, before chemotherapy (D1) Dexamethasone 10 mg, IV, before chemotherapy (D1)...” NCT01052844 ↗ “Anesthesia will be maintained with Sevoflurane, Magnesium, Lidocaine, Ketamine, Decadron, Ondansetron, and Ketorolac at a concentration range/dose(s) based on the clinical need...” NCT03367988 ↗ “Day 1: Aprepitant 125mg QD (once daily); Ondansetron 8mg BD (twice daily); Dexamethasone 12mg QD (Aprepitant, Ondansetron and Dexamethasone to be take 60 minutes before...” NCT07455955 ↗ “Granisetron Transdermal Delivery System (GTDS) efficacy compared with the ondansetron efficacy with regard to Complete Response (CR) of Chemotherapy Induced Nausea and Vomiting (CINV).” NCT01659775 ↗ “Pramipexole group: Consenting individuals meeting accession criteria will start pramipexole 2.0mg daily dose (1.0mg twice a day) with ondansetron 16mg daily dose (8mg twice a day).” NCT03642964 ↗ “Patients will receive ondansetron (0.1 mg / kg dose of 4mg cap) associated with dexamethasone (0.15 mg / kg dose of 5mg ceiling) or dexamethasone (0.15 mg / kg) or placebo” NCT01297010 ↗ “Comparison Between Propofol, Ondansetron and Pregabalin for Control of Emetic Attacks During Caesarean Delivery With Spinal Anesthesia: Randomized Clinical Trial” NCT06300346 ↗ Show 434 more sources
Known as	A04AA01	ChEMBL registry synonym — accepted as the source's own label CHEMBL46 ↗
Known as	AD04	“AD04 (ondansetron)” NCT04101227 ↗
Known as	BEKINDA	“Randomized, Placebo-Controlled, Phase 3 Trial of RHB-102 (BEKINDA) (Ondansetron 24 mg Bimodal Release Tablets) for Acute Gastroenteritis.” NCT02246439 ↗ 1 “BEKINDA (Ondansetron 12 mg Bimodal Release Tablets)” NCT02757105 ↗
Known as	Demorem	ChEMBL registry synonym — accepted as the source's own label CHEMBL46 ↗
Known as	Desmethylondansetron	ChEMBL registry synonym — accepted as the source's own label CHEMBL46 ↗
Known as	EUR-1025	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01036854 ↗
Known as	GR 38032F	ChEMBL registry synonym — accepted as the source's own label CHEMBL46 ↗
Known as	GR-38032	ChEMBL registry synonym — accepted as the source's own label CHEMBL46 ↗
Known as	GR-C507/75	ChEMBL registry synonym — accepted as the source's own label CHEMBL46 ↗
Known as	NS003	“NS003 Ondansetron HCl microspheres powder for nasal application” NCT07868861 ↗
Known as	NSC-665799	ChEMBL registry synonym — accepted as the source's own label CHEMBL46 ↗
Known as	NSC-757870	ChEMBL registry synonym — accepted as the source's own label CHEMBL46 ↗
Known as	Odansetron hydrochloride	ChEMBL registry synonym — accepted as the source's own label CHEMBL46 ↗
Known as	OND	“The combination of dexamethasone (DEX), ondansetron (OND) and droperidol (DRO) is efficacious in preventing postoperative nausea and vomiting in adults, but has not been well...” PMID 28505233 ↗ Jun 2017
Known as	Ond-PR1	“Single oral dose of 8 mg of ondansetron pulsatile-release formulation 1 (Ond-PR1)” NCT01290276 ↗
Known as	Ond-PR2	“Single oral dose of 8 mg ondansetron pulsatile-release formulation 2 (Ond-PR2)” NCT01290276 ↗
Known as	Ondalenz	“oral ondansetron in the form of an oral soluble film 4 mg strip (Ondalenz, 4 mg orodispersible films of Nerhadou International Co.)” NCT07088601 ↗ 5 “Pediatric patients will receive ondansetron lozenge 4 mg (Ondalenz ©), 2 hours before surgery as a study group.” NCT06423820 ↗ “Patients will receive ondansetron lozenge 4 mg (Ondalenz ©), 2 hours before surgery.” NCT06254131 ↗ “Patients will receive ondansetron lozenge 4 mg (Ondalenz ©), 2 hours before surgery.” NCT07511491 ↗ “Patients will receive ondansetron lozenge 4 mg (Ondalenz ©), 2 hours before surgery.” NCT06423807 ↗ “Patients will receive ondansetron lozenge 4 mg (Ondalenz ©), 2 hours before surgery.” NCT07489742 ↗
Known as	Ondansetron (as hydrochloride)	ChEMBL registry synonym — accepted as the source's own label CHEMBL46 ↗
Known as	Ondansetron (Zofran)	“Ondansetron (Zofran)” NCT00781768 ↗ 1 “ondansetron (Zofran)” NCT02724033 ↗
Known as	Ondansetron Accord	“Ondansetron (Ondansetron Accord 2mg/ml, 2 ml solution, Accord Healthcare Limited, Great Britain) in a dose of 4 mg will be administered intravenously” NCT06609993 ↗
Known as	Ondansetron HCl	“Ondansetron HCl 8 mg OD Tablet (test) dosed in first period followed by Zofran® 8 mg ODT (reference) dosed in second period” NCT00934180 ↗ 3 “NS003 Ondansetron HCl microspheres powder for nasal application” NCT07868861 ↗ “Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)” NCT00946387 ↗ “Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)” NCT00947128 ↗
Known as	Ondansetron Hydrochloride	“ondansetron hydrochloride(8mg, i.v. day 1-day 3)” NCT04536558 ↗ 3 “Drug: Ondansetron Hydrochloride” NCT02953210 ↗ “IV ondansetron hydrochloride” NCT00431236 ↗ NCT00429702 ↗
Known as	Ondansetron hydrochloride dihydrate	ChEMBL registry synonym — accepted as the source's own label CHEMBL46 ↗
Known as	Ondansetron hydrochloride hydrate	ChEMBL registry synonym — accepted as the source's own label CHEMBL46 ↗
Known as	Ondansetron hydrochloride preservative free	ChEMBL registry synonym — accepted as the source's own label CHEMBL46 ↗
Known as	Ondansetron monohydrochloride	ChEMBL registry synonym — accepted as the source's own label CHEMBL46 ↗
Known as	Ondasetron	“Drug: Ondasetron 4mg” NCT07084753 ↗
Known as	Ondemet	ChEMBL registry synonym — accepted as the source's own label CHEMBL46 ↗
Known as	RHB-102	“Randomized, Placebo-Controlled, Phase 3 Trial of RHB-102 (BEKINDA) (Ondansetron 24 mg Bimodal Release Tablets) for Acute Gastroenteritis.” NCT02246439 ↗
Known as	Setofilm	ChEMBL registry synonym — accepted as the source's own label CHEMBL46 ↗
Known as	SN 307	ChEMBL registry synonym — accepted as the source's own label CHEMBL46 ↗
Known as	ZOFATRONE	“Patients will receive 8 mg of ondansetron (ZOFATRONE®, 8 mg/4 mL, EVA Pharma, Egypt)” NCT06850740 ↗
Known as	Zofran	“Treatment B: single dose of Zofran ODT (containing ondansetron 8 mg) was orally administered, allowed to dissolve, swallowed with saliva, followed with 240 mL room temperature...” NCT01217190 ↗ 30 “Ondansetron HCl 8 mg OD Tablet (test) dosed in first period followed by Zofran® 8 mg ODT (reference) dosed in second period” NCT00934180 ↗ “Eligible patients were randomized to Sancuso patch or Zofran groups and received the assigned treatment for 5days.” NCT01659775 ↗ “ondansetron (Zofran) tablets combined with a medicine called dexamethasone given IV” NCT00781768 ↗ “To compare the single-dose bioavailability of Ondansetron ODT 8 mg and Zofran 8 mg” NCT00653458 ↗ “D1 Zofran 8mg pre-Cyclophosphamide 300mg/mg2 po and D3 Ipilimumab 10mg/kg iv” NCT01740401 ↗ “The usual treatment for nausea/vomiting is a drug called Zofran” NCT03125811 ↗ “ondansetron 4mg (Zofran; GlaxoSmithKline, Alexandria, USA” NCT06017167 ↗ “Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)” NCT00947128 ↗ “Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)” NCT00946387 ↗ “ondansetron (Zofran)” NCT00027079 ↗ Show 20 more sources
Known as	zofran - ondansetron	“zofran - ondansetron” NCT01536691 ↗
Known as	Zofran ODT	“Ondansetron HCl with the already marketed reference formulation Zofran ODT under fasting conditions” NCT00934180 ↗ 1 “Single dose of Zofran ODT (containing ondansetron 8 mg) administered without water” NCT01220167 ↗
Known as	Zofran preservative free	ChEMBL registry synonym — accepted as the source's own label CHEMBL46 ↗
Known as	Zofran, Ondansetron hydrochloride	“Zofran (ondansetron hydrochloride)” NCT01290276 ↗ 1 “Zofran, Ondansetron hydrochloride” NCT05378113 ↗
Known as	Zophren	ChEMBL registry synonym — accepted as the source's own label CHEMBL46 ↗
Known as	Zuplenz	ChEMBL registry synonym — accepted as the source's own label CHEMBL46 ↗
Action	Inhibit	“Serotonin 3a (5-HT3a) receptor antagonist” CHEMBL46 ↗ 1 “a 5HT3 antagonist” NCT00000289 ↗
Modality	Other / unclassified	“Ondansetron is a selective 5-HT3 receptor antagonist.” NCT00967499 ↗
Route	Oral	“ondansetron orally” NCT00005994 ↗
Target	HTR3A	“Serotonin 3a (5-HT3a) receptor antagonist” CHEMBL46 ↗